BioVeda Capital

Sensely is a developer of a conversational platform that enhances the experience of insurance plan members and patients through avatar and chatbot technology. The company offers virtual assistant solutions tailored for insurance companies, pharmaceutical clients, and hospital systems globally. By leveraging conversational interfaces, Sensely enables these organizations to engage with their members in a way that merges the empathy of human interaction with the efficiency and scalability of technological solutions. This approach aims to elevate brand preference and influence member behavior, ultimately improving overall healthcare communication.

Founded in 2013, CXA Group is Asia's leading Insurtech company, transforming employee benefits by shifting focus from treatment to prevention. Its AI-driven platform enables employees to proactively manage their health through personalized insurance and wellness offerings, while employers gain insights into workforce health analytics to improve productivity and engagement.

ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.

Biolidics Limited is a medical technology company based in Singapore that specializes in the development of cell enrichment systems for cancer-related applications, including diagnosis, prognosis, treatment selection, and monitoring. Founded in 2009, the company has created the ClearCell FX1 System, an automated in vitro diagnostic device designed to separate and enrich cancer cells from blood samples. Biolidics engages in research, development, and marketing in the fields of biotechnology, life sciences, and medical technology, serving a diverse clientele that includes academic institutions, hospitals, and laboratories across Singapore, China, Hong Kong, Japan, the United States, and European Union countries. The company also collaborates strategically with Sysmex Corporation and generates significant revenue from its laboratory services segment, which provides essential laboratory operations and services to various customers.

ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Inspired Capital plc specializes in providing a variety of lending products tailored for small and medium-sized enterprises (SMEs) in the United Kingdom. The company offers an array of financing options including business cash loans, asset finance, trade finance, construction finance, recruitment finance, transport finance, enterprise finance guarantees, factoring, and invoice discounting. Inspired Capital seeks to simplify the borrowing process for small businesses, ensuring that they have quick and efficient access to the funds necessary for growth, whether that involves expanding operations, hiring new staff, investing in equipment, or managing cash flow. Originally known as Renovo Group plc, the company rebranded in August 2014 and is headquartered in Bristol. As of August 2015, Inspired Capital plc was taken private.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Renovis, Inc. is a biopharmaceutical company focused on developing innovative drugs for neurological diseases and disorders. The company is actively engaged in creating treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing advanced techniques in molecular biology, medicinal chemistry, and pharmacology, Renovis identifies and selects small molecule drug candidates that adhere to rigorous development standards. Through a combination of in vitro and in vivo studies, drug metabolism and pharmacokinetics assessments, and toxicological evaluations, Renovis aims to deliver effective therapeutic solutions to address significant unmet medical needs in neurology.

NewBiotics is a U.S.-based biotechnology company founded in 1997, specializing in the discovery and development of therapeutics for cancer and infectious diseases. The company focuses on leveraging the mechanisms of drug resistance to create innovative drug molecules. Notably, NewBiotics has identified the presence of double-minute chromosomes, which are unique to cancer cells, and has developed technology for the purification of double-minute DNA from tumor cells. This approach aims to transform the challenges posed by drug resistance into therapeutic advantages, enabling the development of more effective treatments. The company was acquired by Celmed Biosciences in 2004, further integrating its expertise into a broader therapeutic framework.